Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 9/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988882 | 1.00 | EPHX2 (0.47) | EPHX2GAANAAASCN9ANFKB1 | |
| SCHEMBL6177311 | 0.87 | EPHX2 (0.47) | EPHX2GAANAAASCN9ANFKB1 | |
| SCHEMBL8210416 | 0.87 | EPHX2 (0.47) | EPHX2GAANAAASCN9ANFKB1 | |
| SCHEMBL15811245 | 0.83 | EPHX2 (0.51) | EPHX2GAANAAANFKB1NFKB2 | |
| SCHEMBL6176701 | 0.83 | EPHX2 (0.51) | EPHX2GAANAAANFKB1NFKB2 | |
| SCHEMBL17324359 | 0.83 | EPHX2 (0.46) | EPHX2GAANAAASCN9ANFKB1 | |
| SCHEMBL20050045 | 0.83 | EPHX2 (0.46) | EPHX2GAANAAASCN9ANFKB1 | |
| SCHEMBL3485516 | 0.82 | EPHX2 (0.62) | EPHX2GAANAAASCN9ANFKB1 | |
| SCHEMBL949512 | 0.82 | EPHX2 (0.62) | EPHX2GAANAAASCN9ANFKB1 | |
| SCHEMBL645858 | 0.82 | EPHX2 (0.62) | EPHX2GAANAAASCN9ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414049-B2 | 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414049-B2 | 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414049-B2 | 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20080103133-A1 | 4-OXO-2,3,4,5-TETRAHYDRO-BENZO[b][1,4]DIAZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| US-20080103133-A1 | 4-OXO-2,3,4,5-TETRAHYDRO-BENZO[b][1,4]DIAZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| US-20080103133-A1 | 4-OXO-2,3,4,5-TETRAHYDRO-BENZO[b][1,4]DIAZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103133-A1 | 4-OXO-2,3,4,5-TETRAHYDRO-BENZO[b][1,4]DIAZEPINE DERIVATIVES | BACE1, BACE2, PSEN1 | EPHX2 888/4885GAA 271/4885NAAA 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.